Fadare Oluwole, Renshaw Idris L, Liang Sharon X
Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):352-9. doi: 10.1097/PAI.0b013e3182013441.
Bone morphogenetic proteins (BMPs) are extracellular, multifunctional growth factors that constitute the largest subset of the transforming growth factor β superfamily. BMP2 is involved in cardiovascular embryogenesis, in addition to a variety of other postnatal functions, such as neovascularization, osteoinduction, tumor signaling, and in the uterus, stromal decidualization at the implantation site. Estrogen receptor signaling is common in smooth muscle tumors of the uterus, and preclinical models suggest significant interactions between BMP2 and estrogen receptor-mediated signaling. The purpose of this study is to define the patterns of BMP2 expression, as assessed by immunohistochemistry, in smooth muscle tumors and other tissues of the uterine corpus, and to establish whether BMP2 expression has any prognostic significance in uterine leiomyosarcomas. BMP2 was positive (cytoplasmic pattern, typically focal) in 24% of leiomyosarcomas and 20.7% of leiomyomata, but was either infrequently expressed or not expressed in all other tissues evaluated, including normal myometrium and endometrium, endometrial stromal tumors, typical adenomyoma, adenomyosis, and serosal endometriosis. The endothelial cells of small, thin-walled vessels were frequently, but not invariably immunoreactive for BMP2. There was no significant difference between BMP2⁺ and BMP⁻ leiomyosarcomas regarding average tumor size, average patient age, microvessel density, and proportions with high tumor grade, advanced stage and frequency of death from disease on follow-up. Two (29%) of 7 BMP2⁺ leiomyosarcomas were estrogen receptor+, compared with 5 (50%) of 10 BMP2⁻ leiomyosarcomas, a statistically insignificant difference (P=0.62). It is concluded that BMP2 is only expressed in a minority of smooth muscle tumors of the uterine corpus, and lacks prognostic significance in leiomyosarcomas. BMP2 is rarely expressed in the other nonendothelial tissues of the human uterine corpus that were evaluated. The significance of frequent BMP2 expression in small vessels of the uterus requires further investigation.
骨形态发生蛋白(BMPs)是细胞外多功能生长因子,构成转化生长因子β超家族中最大的亚类。BMP2除参与多种出生后的功能,如新生血管形成、骨诱导、肿瘤信号传导,以及在子宫中参与着床部位的基质蜕膜化外,还参与心血管胚胎发育。雌激素受体信号传导在子宫平滑肌瘤中很常见,临床前模型提示BMP2与雌激素受体介导的信号传导之间存在显著相互作用。本研究的目的是通过免疫组织化学评估来确定BMP2在子宫体平滑肌瘤和其他组织中的表达模式,并确定BMP2表达在子宫平滑肌肉瘤中是否具有任何预后意义。BMP2在24%的平滑肌肉瘤和20.7%的平滑肌瘤中呈阳性(细胞质模式,通常为局灶性),但在所有其他评估组织中很少表达或不表达,包括正常子宫肌层和子宫内膜、子宫内膜间质肿瘤、典型子宫腺肌病、子宫腺肌症和浆膜子宫内膜异位症。小的薄壁血管内皮细胞对BMP2常呈免疫反应性,但并非总是如此。在平均肿瘤大小、平均患者年龄、微血管密度以及高肿瘤分级、晚期别和随访期间疾病死亡频率的比例方面,BMP2阳性和阴性的平滑肌肉瘤之间没有显著差异。7例BMP2阳性平滑肌肉瘤中有2例(29%)雌激素受体阳性,而10例BMP2阴性平滑肌肉瘤中有5例(50%)雌激素受体阳性,差异无统计学意义(P=0.62)。结论是,BMP2仅在少数子宫体平滑肌瘤中表达,在平滑肌肉瘤中缺乏预后意义。在评估的人类子宫体其他非内皮组织中,BMP2很少表达。子宫小血管中BMP2频繁表达的意义需要进一步研究。